3 Cannabis Stocks Under Accumulation: MedX Holdings, Inc. (MEDH), CV Sciences, Inc. (CVSI), CBD of Denver, Inc. (CBDD)


MedX Holdings Inc. (OTC: MEDH) is a brands and acquisition company. Our vision is to develop brands and the ancillary infrastructure needed to create demand through vertical integration, strategic partnerships, licensing and franchising while providing solutions to the emerging hemp and cannabis industry.

The company recently issued a corporate update and outlook against the backdrop of the January 2021 legislative session in Texas.

Currently, 15 states and Washington D.C. permit marijuana for adult recreational use, while 36 states allow it for medical purposes. Ahead of the January 2021 legislative session, Texas lawmakers have pre-filed several bills that would expand the state’s medicinal cannabis program and add it to the list of states legalizing adult-use.

MEDH, now headquartered in Austin, Texas, continues to prepare for these impending legislative changes, finalizing agreements and advancing relationships that will support its growth-by-acquisition strategy and vertical integration.

Anticipating that full legalization is inevitable, the Company’s franchise development team is preparing an aggressive growth campaign to re-introduce cannabis to an expanded marketplace. Management projects that the convergence of coffee and cannabis products will be an effective way to reach consumers previously hesitant to cannabis consumption.

Additionally, the Company’s farming assets will begin planting and farming hemp this spring with first harvest expected in the second quarter of 2021.

“We hope to complete our plans to merge and acquire internal and external brands and entities in Q2 and throughout the remainder of 2021,” stated MEDH CEO Hans Enriquez. “We look forward to a favorable outcome of the legislative session and expect expansion to the hemp and medical program in Texas. We are excited to execute our operational strategies in 2021 and prepare for the next phase of growth.”

CV Sciences, Inc. (OTC:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 6,200 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications.  With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.  PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

The company recently announced the launch of ProCBD™, a full product line of clinical strength CBD products available exclusively through health practitioners.

Clinical strength ProCBD™ products were created with the CV Sciences Medical Advisory Board specifically to meet patient needs and to fit seamlessly with existing care plans. ProCBD™ is the only CBD supported by published investigations, randomized controlled trial, and post marketing safety review.

Formulated with CV Sciences’ decarboxylated and distilled hemp extract for concentrated CBD levels that are best used under a specialist’s care, ProCBD™ is available in Roll-On, Liquids and Softgels. The ProCBD™ product line is non-GMO, gluten free, plant-based and vegan friendly.

CBD of Denver, Inc. (OTC: CBDD) a full-line CBD and Hemp oil company (“CBDD”) and a producer and distributor of Cannabis and CBD products in Switzerland, Europe and the US. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis. Through our brands, Rockflowr and BlackPearlCBD we have built a strong customer base by focusing on top quality products and meaningful customer relationships. For more information, visit www.cbdofdenver.com.

CBD of Denver, Inc. has achieved a total revenue of USD $8,651,240.00 for the fourth quarter ended December 31, 2020, compared to revenue of USD $5,963,820.00 during the third quarter ended September 30, 2020, an increase of more than 40%. “It was a tough quarter,” states Managing Director of Sales Pascal Siegenthaler, “as we are in a partial lockdown in Switzerland since November and there is now a full lockdown in most of the European countries. Nevertheless, due to our excellent sales team continuously increasing our customer base we were able to achieve such a good result.”

The re-branding process for Rockflowr Exchange, Rockflowr Retail and Rockflowr Production is in line with the planning with the launch to be as planned in January 2021. The Company also expects to announce some new product lines soon.

“The first quarter of this year will be a very important quarter for our company,” states Marcel Gamma, CEO CBD of Denver, “as we look to continue our success and implement new processes and procedures to further improve our operational excellence and better prepare the organization for future growth.”


Please enter your comment!
Please enter your name here